# OnCo record paper-magnetismm-3-elranatamab-natmed-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-magnetismm-3-elranatamab-natmed-2023" ;
schema:name "MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response"@en ;
schema:description "Elranatamab produced responses in 61% of heavily pretreated myeloma patients and showed that dosing can be thinned to every two weeks once patients respond."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , ;
schema:sameAs ;
schema:datePublished "2023"^^xsd:gYear ;
schema:author "Lesokhin AM, Tomasson MH, Arnulf B, et al." ;
onco:related , ;
onco:cancers ;
onco:technologies , ;
onco:targets , , ;
onco:drugs , , ;
onco:companies ;
onco:terms , ;
onco:trials , ;
onco:bottlenecks , ;
onco:journals .